A Study of the Safety and Tolerability of BMS-986183 in Patients With Liver Cancer

NCT02828124 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

25

Enrollment

INDUSTRY

Sponsor class

Stopped Business objectives have changed

Conditions

Hepatocellular Carcinoma

Interventions

BIOLOGICAL: BMS-986183
BIOLOGICAL: Nivolumab

Sponsor

Bristol-Myers Squibb